Table 3 Sensitivity, specificity and balanced accuracy of individual markers to predict a lower GI tumor in the test and expansion cohorts using different cut-offs
Test cohort | |||||||||
---|---|---|---|---|---|---|---|---|---|
Binary criteria (absent versus present) | Sensitivity | 95% CI | Specificity | 95% CI | Accuracy | 95% CI | |||
SATB2 present | 0.90 | 0.85 | 0.94 | 0.87 | 0.81 | 0.92 | 0.89 | 0.85 | 0.92 |
CK7 absent | 0.81 | 0.75 | 0.86 | 0.97 | 0.94 | 0.99 | 0.88 | 0.84 | 0.91 |
PAX8 absent | 0.97 | 0.94 | 0.99 | 0.45 | 0.37 | 0.53 | 0.76 | 0.72 | 0.81 |
CDX2 present | 0.98 | 0.96 | 1.00 | 0.30 | 0.23 | 0.38 | 0.71 | 0.66 | 0.75 |
CK20 present | 0.87 | 0.82 | 0.91 | 0.18 | 0.12 | 0.25 | 0.59 | 0.54 | 0.64 |
Binary criteria (diffuse versus non-diffuse) | |||||||||
CK7 nondiffuse | 0.92 | 0.88 | 0.95 | 0.91 | 0.85 | 0.95 | 0.92 | 0.88 | 0.94 |
SATB2 diffuse | 0.80 | 0.74 | 0.85 | 0.94 | 0.86 | 0.97 | 0.86 | 0.82 | 0.89 |
CDX2 diffuse | 0.81 | 0.76 | 0.86 | 0.83 | 0.75 | 0.89 | 0.82 | 0.78 | 0.86 |
PAX8 nondiffuse | 0.97 | 0.94 | 0.99 | 0.12 | 0.07 | 0.18 | 0.63 | 0.58 | 0.68 |
CK20 diffuse | 0.71 | 0.64 | 0.77 | 0.56 | 0.48 | 0.64 | 0.65 | 0.60 | 0.70 |
Expansion cohort | |||||||||
Binary criteria (absent versus present) | |||||||||
SATB2 present | 0.95 | 0.91 | 0.97 | 0.88 | 0.83 | 0.92 | 0.92 | 0.88 | 0.94 |
PAX8 absent | 0.97 | 0.94 | 0.99 | 0.41 | 0.35 | 0.49 | 0.71 | 0.67 | 0.75 |
Binary criteria (diffuse versus non-diffuse) | |||||||||
SATB2 diffuse | 0.80 | 0.74 | 0.85 | 0.94 | 0.89 | 0.97 | 0.96 | 0.83 | 0.90 |
PAX8 nondiffuse | 0.97 | 0.94 | 0.99 | 0.14 | 0.09 | 0.19 | 0.58 | 0.53 | 0.63 |